JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment

Reuters

05-28

JW Cayman <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment

JW Cayman Therapeutics Co. Ltd., a biotechnology company specializing in cell immunotherapy products, has announced that the National Medical Products Administration of China (NMPA) has accepted the supplemental Biological License Application (sBLA) for Carteyva® (relmacabtagene autoleucel injection). The product is proposed as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who are ineligible for autologous stem cell transplantation. This marks the fourth sBLA submission for Carteyva® by JW Therapeutics, reflecting the company's ongoing efforts in the development and commercialization of cell immunotherapy solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538423760"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538423760\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538423760?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 16:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538423760","market":"nz","top_or_hot":-1,"title":"JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      JW Cayman <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        JW Cayman Therapeutics Co. Ltd., a biotechnology company specializing in cell immunotherapy products, has announced that the National Medical Products Administration of China (NMPA) has accepted the supplemental Biological License Application (sBLA) for Carteyva® (relmacabtagene autoleucel injection). The product is proposed as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who are ineligible for autologous stem cell transplantation. This marks the fourth sBLA submission for Carteyva® by JW Therapeutics, reflecting the company's ongoing efforts in the development and commercialization of cell immunotherapy solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-28 16:57</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      JW Cayman <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        JW Cayman Therapeutics Co. Ltd., a biotechnology company specializing in cell immunotherapy products, has announced that the National Medical Products Administration of China (NMPA) has accepted the supplemental Biological License Application (sBLA) for Carteyva® (relmacabtagene autoleucel injection). The product is proposed as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who are ineligible for autologous stem cell transplantation. This marks the fourth sBLA submission for Carteyva® by JW Therapeutics, reflecting the company's ongoing efforts in the development and commercialization of cell immunotherapy solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDLbrjft9:1","article_id":"2538423760","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538423760","pubTimestamp":1748422651,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment. JW Cayman Therapeutics Co. Ltd., a biotechnology company specializing in cell immunotherapy products, has announced that the National Medical Products Administration of China  has accepted the supplemental Biological License Application  for Carteyva . The product is proposed as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma  who are ineligible for autologous stem cell transplantation. This marks the fourth sBLA submission for Carteyva by JW Therapeutics, reflecting the company's ongoing efforts in the development and commercialization of cell immunotherapy solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"JW Cayman Therapeutics宣布NMPA受理CAR-T疗法治疗大B细胞淋巴瘤的补充生物制剂许可申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02126":0.9},"content_text":"JW Cayman Therapeutics Announces NMPA Acceptance of Supplemental Biological License Application for CAR-T Therapy in Large B-Cell Lymphoma Treatment\n    \n\n        JW Cayman Therapeutics Co. Ltd., a biotechnology company specializing in cell immunotherapy products, has announced that the National Medical Products Administration of China (NMPA) has accepted the supplemental Biological License Application (sBLA) for Carteyva® (relmacabtagene autoleucel injection). The product is proposed as a second-line treatment for patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) who are ineligible for autologous stem cell transplantation. This marks the fourth sBLA submission for Carteyva® by JW Therapeutics, reflecting the company's ongoing efforts in the development and commercialization of cell immunotherapy solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}